INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 45h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03FWFogarty Patrick W0B / 60S60 trades$277K
  4. 04SJSheena Jonathan0B / 57S57 trades$3.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SLSpeiser Michael L0B / 35S35 trades$14.00M
  9. 09RARothblatt Martine A0B / 33S33 trades$5.50M
  10. 10RJRubinstein Julie0B / 32S32 trades$5.48M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

71,584 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
ON
Olmstead NathanSVP and CFO
PENGPenguin Solutions, Inc.
Tax withholding
F$60K
2,988 sh
Jan 20, 2026Jan 21, 2026
Page 1432 of 1790
← PrevNext →
traded Jan 20, 2026
+1d
SEC Form 4

Evidence

12
MO
Marquez OctavioDirector, President and CEO
DBDDIEBOLD NIXDORF, Inc
Tax withholding
F$219K
3,136 sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

12
DD
DeSantis Dean10% Owner
CELHCelsius Holdings, Inc.
Other acquisition or disposition
J—
120.0K sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC Form 4

Evidence

11
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Grant or award
A—
100.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

11
OO
Okupe OluyemiChief Financial Officer
HIMSHims & Hers Health, Inc.
Open-market sale · 10b5-1 plan
SELL$275K
9,067 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC Form 4

Evidence

11
CB
Cree BrianPresident
VTSVitesse Energy, Inc.
Open-market sale · 10b5-1 plan
SELL$28K
1,440 sh
Jan 21, 2026Jan 21, 2026
traded Jan 21, 2026
+0dSEC Form 4

Evidence

11
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Grant or award
A—
2,425 sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

11
AK
Audhya Paul K.CHIEF MEDICAL OFFICER
KALVKalVista Pharmaceuticals, Inc.
Grant or award
A—
100.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

11
SN
Sweeny NicoleChief Commercial Officer
KALVKalVista Pharmaceuticals, Inc.
Grant or award
A—
100.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

11
SD
Smith DironEVP, Chief Financial Officer
ITGRInteger Holdings Corp
Grant or award
A—
7,091 sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

11
MA
Mayes Patrick AEVP & Chief Scientific Officer
INCYINCYTE CORP
Grant or award
A—
4,218 sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

11
SM
Small MartinCFO & Senior Managing Director
BLKBlackRock, Inc.
Option exercise
M—
27.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

11
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Grant or award
A—
14.2K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

10
DA
D'Amico AndrewDirector
VICRVICOR CORP
Open-market sale · 10b5-1 plan
SELL$31K
200 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC Form 4

Evidence

10
MI
Mat IshbiaDirector, President and CEO, 10% Owner
UWMCUWM Holdings Corp
Derivative conversion · 10b5-1 plan
C—
6.60M sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

9
CJ
Cambre JeromeVice President of Sales
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
40.7K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
CJ
Cambre JeromeVice President of Sales
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
10.2K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
BS
Bowser Douglas SDirector
HASHASBRO, INC.
Grant or award
A—
750 sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
FG
Frey Anthony GeorgeSVP and Chief Revenue Officer
PENGPenguin Solutions, Inc.
Tax withholding
F$12K
610 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC Form 4

Evidence

9
MM
Moore MichaelPresident
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
118.8K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
VC
Vernon CarlaDirector
HASHASBRO, INC.
Grant or award
A—
750 sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
MM
Moore MichaelPresident
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
29.7K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
FT
Fitzgerald TraeChief Financial Officer
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
46.7K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
FT
Fitzgerald TraeChief Financial Officer
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
11.7K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
SA
Senn AndrewSVP, Strategy and Business Dev
ITGRInteger Holdings Corp
Option exercise
M—
363 sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
FW
Frazier WilliamDirector, Chief Medical Officer
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
2,922 sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
HC
Hoyt CaseyDirector, Chief Executive Officer
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
43.0K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
BE
Buss Jessica EDirector, Chief Executive Officer
LPROOpen Lending Corp
Grant or award
A—
941.2K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
HC
Hoyt CaseyDirector, Chief Executive Officer
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
172.2K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
FW
Frazier WilliamDirector, Chief Medical Officer
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
11.7K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
TJ
Trahan JeremyGeneral Counsel
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
50.4K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
SA
Senn AndrewSVP, Strategy and Business Dev
ITGRInteger Holdings Corp
Tax withholding
F$31K
361 sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
SA
Senn AndrewSVP, Strategy and Business Dev
ITGRInteger Holdings Corp
Option exercise
M—
2,224 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC Form 4

Evidence

9
SA
Senn AndrewSVP, Strategy and Business Dev
ITGRInteger Holdings Corp
Option exercise
M—
363 sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
TJ
Trahan JeremyGeneral Counsel
VMDVIEMED HEALTHCARE, INC.
Grant or award
A—
12.6K sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

9
SD
Smith DironEVP, Chief Financial Officer
ITGRInteger Holdings Corp
Option exercise
M—
1,709 sh
Jan 19, 2026Jan 21, 2026
traded Jan 19, 2026
+2dSEC Form 4

Evidence

8
SC
Selecky ChristobelDirector
IBRXImmunityBio, Inc.
Option exercise · 10b5-1 plan
M$149K
50.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC Form 4

Evidence

5
SD
Smith DironEVP, Chief Financial Officer
ITGRInteger Holdings Corp
Option exercise
M—
292 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC Form 4

Evidence

5
SD
Smith DironEVP, Chief Financial Officer
ITGRInteger Holdings Corp
Tax withholding
F$6,131
72 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC Form 4

Evidence

5
MJ
Morrissey Michael JamesEVP, Head of Tech. Operations
INCYINCYTE CORP
Tax withholding
F$44K
429 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC Form 4

Evidence